Abstract
Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein. In addition, the reduced recognition of several compounds by multi-drug-resistance-related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity. It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.
Keywords: Taxoids, Cytotoxicity, Taxus, TXD258, RPR 109881A, BMS 185660, BMS 188797, BMS 184476
Current Pharmaceutical Design
Title: Preclinical Evaluation of New Taxoids
Volume: 7 Issue: 13
Author(s): M. -C. Bissery
Affiliation:
Keywords: Taxoids, Cytotoxicity, Taxus, TXD258, RPR 109881A, BMS 185660, BMS 188797, BMS 184476
Abstract: Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein. In addition, the reduced recognition of several compounds by multi-drug-resistance-related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity. It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.
Export Options
About this article
Cite this article as:
Bissery -C. M., Preclinical Evaluation of New Taxoids, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397465
DOI https://dx.doi.org/10.2174/1381612013397465 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology An Overview of Pathogenesis and Pathophysiology in Endometriosis
Current Women`s Health Reviews Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Modulation of Cytotoxicity of Benzamide Riboside by Expression of NMN Adenylyltransferase
Current Medicinal Chemistry Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Nano Hydroxyapatite (nano-HAp): A Potential Bioceramic for Biomedical Applications
Current Nanomaterials Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry The Application of Natural Products in Cancer Therapy by Targeting Apoptosis Pathways
Current Drug Metabolism Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Overexpression of miR-340-5p Inhibits Skin Fibroblast Proliferation by Targeting Kruppel-like Factor 2
Current Pharmaceutical Biotechnology Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Recombination Functions of Replication Protein A
Current Organic Chemistry Cyclodextrin Inclusion Complexes Loaded in Particles as Drug Carrier Systems
Current Topics in Medicinal Chemistry Intracellular ROS Generation Mediates Maleimide-induced Cytotoxicity in Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry